Editorial
|
|
|
False truths, misconceptions and unfounded beliefs
|
|
|
Marketing Authorisations
|
|
|
No clear advantage
|
|
|
|
|
|
COPD: another antimuscarinic with cardiac adverse effects that require monitoring
|
|
|
|
|
|
Delays pain onset, cytotoxic therapy, and possibly death
|
|
|
|
|
Adverse Effects
|
|
|
Monitor patients for changes in behaviour
|
|
|
|
|
|
Cardiovascular risk for both mother and child
|
|
|
|
|
|
Serious cardiovascular and gastrointestinal disorders
|
|
|
|
|
|
Rhythm and conduction disorders
|
|
|
|
|
|
About 900 reports, providing useful information
|
|
|
|
|
|
Rare, serious adverse effect
|
|
|
|
Reviews
|
|
|
Allowing patients to self-initiate antibiotic therapy
|
|
|
|
|
|
Drugs of choice and drugs to avoid
|
|
|
|
Outlook
|
|
|
Wise substitution ensures risk-free cost savings
|
|
|
|